Dare Bioscience

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Daré Bioscience reports Q1 progress in women's health innovation

Daré Bioscience showcased progress in Q1 2024 with achievements in product commercialization and pipeline advancements, despite a reported comprehensive loss.
The company's focus on women's health innovation and commitment to driving value for stakeholders position them well for future growth.
While facing financial challenges and competitive pressures, Daré Bioscience has opportunities to capitalize on its strong pipeline and attract investor interest.
Continued momentum in Phase III studies and technology development present avenues for growth and market expansion in the women's health sector.

Dare Bioscience reports strong Q2 earnings, advances women's health therapies

Dare Bioscience delivered a robust Q2 2024 performance marked by cost efficiencies, revenue generation from strategic transactions, and progress in key product developments.
The company's focus on women's health and commitment to advancing therapies position it well for future growth and market leadership in a segment with significant unmet needs.
While facing challenges in market adoption and regulatory interactions, Dare Bioscience has opportunities to drive revenue growth, expand its market presence, and diversify its product portfolio.
Overall, Dare Bioscience's Q2 earnings call reflects a company on a positive trajectory, with a strong financial foundation and a strategic focus on advancing innovative solutions for women's health.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and CEO, will participate in the following February conferences:

Daré Bioscience to Participate in Three February Conferences

Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong Buy

Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?

Dare Bioscience, Inc. (NASDAQ:DARE ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Sabrina Johnson - President and Chief Executive Officer Lisa Walters-Hoffert - Chief Financial Officer John Fair - Chief Strategy Officer Conference Call Participants Kumaraguru Raja - ROTH Capital Operator Welcome to the conference call hosted by Dare Bioscience to review the company's financial results for the quarter ended September 30, 2022 and to provide a general business update. This call is being recorded.

Dare Bioscience, Inc. (DARE) Q3 2022 Earnings Call Transcript

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 27.27% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates

Conference Call and Webcast Today at 4:30 p.m. ET

Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and CEO, will present at the Stifel 2022 Healthcare Conference, being held November 15-16, 2022 in New York, NY.

Daré Bioscience to Present at the Stifel 2022 Healthcare Conference

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 10, 2022, to review its financial results for the quarter ended September 30, 2022 and to provide a Company update.

Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022

Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause

Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study

Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive Product Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive Product

Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and CEO, will participate in two upcoming conferences.

Daré Bioscience to Participate in Two Upcoming Conferences

Dare Bioscience, Inc. (NASDAQ:DARE ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Sabrina Johnson - President, CEO, Secretary & Director John A. Fair - Chief Strategy Officer Lisa Walters-Hoffert - CFO Conference Call Participants Operator Good.

Dare Bioscience, Inc. (DARE) CEO Sabrina Johnson on Q2 2022 Results - Earnings Call Transcript

Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, August 9, 2022, to review its financial results for the quarter ended June 30, 2022 and to provide a Company update.

Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022

SAN DIEGO, July 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will be participating in a virtual panel discussion presented by Maxim Group LLC and hosted by M-Vest, on July 13, 2022 at 11:00 a.m. ET. Additional information regarding the panel is set forth below.

Daré Bioscience to Participate in Maxim Group Women's Health Panel

Meeting to be reconvened solely with respect to Proposal 5 Meeting to be reconvened solely with respect to Proposal 5

Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022

Archer Aviation

Zymergen

Check these penny stocks out for your watchlist right now The post Good Penny Stocks to Buy Now? 3 to Watch in June  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Good Penny Stocks to Buy Now? 3 to Watch in June

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and CEO, will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference. The conference will be held in-person and virtually from May 23-26, 2022, with in-person participation held at the Fountainebleau Miami Beach Hotel in Miami Beach, Florida.

Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference

Dare Bioscience, Inc. (NASDAQ:DARE ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and Chief Executive Officer John Fair - Chief Strategy Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participants Zegbah Jallah - ROTH Capital Partners Douglas Tsao - H.C. Wainwright Kumaraguru Raja - Brookline Capital Markets Operator Welcome to the conference call hosted by Dare Bioscience to review the company's financial results for the year ended March 31, 2022, and to provide a general business update.

Dare Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q1 2022 Results - Earnings Call Transcript

Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update

Supports research to define end-user preferences among U.S. women to informthe design of long-acting injectable hormonal contraception

Daré Bioscience Announces NIH Grant Award

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q4 2021 Results - Earnings Call Transcript

Organon & Co

Organon & Co (NYSE: OGN) will license global rights to Daré Bioscience Inc's (NASDAQ: DARE) Xaciato (clindamycin phosphate vaginal gel, 2%).  Xaciato is an FDA-approved medication for treating bacterial vaginosis (BV) in females 12 years of age and.

Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

Clovis Oncology

First Wave BioPharma

Here's what you need to know about trading penny stocks on March 31st The post Trading Penny Stocks? Top Stock Market News for March 31st, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Dare Bioscience Stock (DARE)